Molecular Partners AG Files 6-K Report

Ticker: MOLN · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001745114

Molecular Partners Ag 6-K Filing Summary
FieldDetail
CompanyMolecular Partners Ag (MOLN)
Form Type6-K
Filed DateMar 30, 2026
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, corporate-update

TL;DR

Molecular Partners AG filed a 6-K on 3/30/26 for period ending 3/31/26. Standard update.

AI Summary

Molecular Partners AG filed a 6-K report on March 30, 2026, for the period ending March 31, 2026. The filing includes a press release (EX-99.1) and other documents related to its operations. The company is involved in Biological Products, excluding Diagnostic Substances.

Why It Matters

This filing provides an update on Molecular Partners AG's corporate activities and financial reporting for the period ending March 31, 2026, which is important for investors tracking the company's progress.

Risk Assessment

Risk Level: low — This filing is a routine 6-K report, which typically contains standard corporate disclosures and does not indicate significant new risks.

Key Players & Entities

  • Molecular Partners AG (company) — Filer
  • 0001745114 (company) — CIK Number
  • 2026-03-30 (date) — Filing Date
  • 2026-03-31 (date) — Period of Report

FAQ

What is the purpose of a 6-K filing?

A 6-K filing is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to provide information that the company makes public in its home country or distributes to its security holders.

When was this 6-K filing accepted by the SEC?

This 6-K filing was accepted by the SEC on March 30, 2026, at 07:06:51.

What is the primary business of Molecular Partners AG?

Molecular Partners AG is primarily involved in Biological Products, excluding Diagnostic Substances, as indicated by its SIC code 2836.

What documents are included in this 6-K filing?

This filing includes the main 6-K document (molecularpartners-form6xkm.htm), an exhibit EX-99.1 (prforagm2026_clare.htm), and a graphic file (image_0.jpg).

What is the mailing and business address of Molecular Partners AG?

The mailing and business address for Molecular Partners AG is WAGISTRASSE 14, Schlieren-Zurich V8 8952.

Filing Stats: 258 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2026-03-30 07:06:51

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MOLECULAR PARTNERS AG (Registrant) Date March 30, 2026 s PATRICK AMSTUTZ Name Patrick Amstutz Title Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.